IGN 101

Drug Profile

IGN 101

Alternative Names: Cancer vaccine (IGN101) - Aphton; Cancer vaccine - Igeneon

Latest Information Update: 17 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG
  • Developer Altropus
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 05 Nov 2009 Clinical development is ongoing in Europe
  • 03 Jun 2008 Efficacy data from a Phase II/III trial in Non-small cell lung cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 07 Feb 2006 Pending directorship approval, Igeneon intends give Celltrion the right of first refusal to further develop and commercialise IGN 101
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top